Compagnie Lombard Odier SCmA Has $3.85 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Compagnie Lombard Odier SCmA lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,565 shares of the pharmaceutical company's stock after selling 864 shares during the quarter. Compagnie Lombard Odier SCmA's holdings in Vertex Pharmaceuticals were worth $3,852,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of VRTX. Vontobel Holding Ltd. raised its stake in Vertex Pharmaceuticals by 66.8% during the fourth quarter. Vontobel Holding Ltd. now owns 188,949 shares of the pharmaceutical company's stock worth $76,090,000 after acquiring an additional 75,653 shares in the last quarter. Bogart Wealth LLC raised its stake in Vertex Pharmaceuticals by 15.8% during the fourth quarter. Bogart Wealth LLC now owns 22,259 shares of the pharmaceutical company's stock worth $8,964,000 after acquiring an additional 3,031 shares in the last quarter. Catalyst Financial Partners LLC raised its stake in Vertex Pharmaceuticals by 3.6% during the fourth quarter. Catalyst Financial Partners LLC now owns 1,125 shares of the pharmaceutical company's stock worth $453,000 after acquiring an additional 39 shares in the last quarter. G&S Capital LLC raised its stake in Vertex Pharmaceuticals by 94.0% during the fourth quarter. G&S Capital LLC now owns 1,267 shares of the pharmaceutical company's stock worth $510,000 after acquiring an additional 614 shares in the last quarter. Finally, Avestar Capital LLC raised its stake in Vertex Pharmaceuticals by 16.4% during the fourth quarter. Avestar Capital LLC now owns 3,674 shares of the pharmaceutical company's stock worth $1,480,000 after acquiring an additional 518 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Up 0.7 %

Shares of Vertex Pharmaceuticals stock traded up $3.11 on Tuesday, reaching $462.11. 1,405,218 shares of the company's stock were exchanged, compared to its average volume of 1,546,074. The company has a market capitalization of $119.01 billion, a P/E ratio of -232.22, a price-to-earnings-growth ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm's 50-day moving average is $435.39 and its two-hundred day moving average is $460.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Ourania Tatsis sold 310 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now directly owns 64,021 shares of the company's stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.20% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on VRTX. JPMorgan Chase & Co. lowered their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating for the company in a research note on Monday, December 23rd. Bank of America lowered their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating for the company in a research note on Thursday, December 19th. Stifel Nicolaus upped their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a "hold" rating in a research note on Monday, December 16th. UBS Group upped their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Finally, Truist Financial upped their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Ten investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $505.57.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.